Triple Negative Breast Cancer (TNBC), i.e., simultaneously negative for ER, PR and HER-2, which accounts for approximately 15–20% of breast cancer (BC), has significantly inferior clinical outcomes than non-TNBC [1, 2]. The gene discussed is ERBB2; the disease is breast cancer.